Key Highlights

  • Arch Capital (NASDAQ:ACGL) trades at USD 109.31, USD 0.95 under its 52-week high of USD 110.26, while premiums slipped 3.0%.
  • Addus HomeCare (NASDAQ:ADUS) trades at USD 125.75, USD 1.31 under its 52-week high of USD 127.06, following a USD 275.0 million agreement.
  • Alerus Financial (NASDAQ:ALRS) rose 4.40% to USD 34.63, USD 0.09 under its 52-week high of USD 34.72.
  • Amneal Pharmaceuticals (NASDAQ:AMRX) is at USD 20.44, down 4.97%, on 5.02 million shares (relative Volume 1.17), with a USD 7.12 billion market cap, a 52-week high of USD 21.68, a P/E of 42.65 and EPS growth of 7,387.50% on the 52-week high screen, captured November 4, 2026.

1. Arch Capital (NASDAQ:ACGL)

On the 52-week high screen, Arch Capital (NASDAQ:ACGL) is at USD 109.31, up 2.77%, on 2.15 million shares (relative volume 1.00), with a USD 37.30 billion market cap, a 52-week high of USD 110.26, a P/E of 8.93 and EPS of USD 12.24, captured November 4, 2026. Highs tell you where a price is, not whether it is cheap, so the results and valuation require review. Net premiums written dropped 3.0% to USD 3,845 million, and the combined ratio increased to 82.5% from 79.8%. Arch bought back USD 1.4 billion of shares, and Book Value per share stood at USD 67.90, so the USD 109.31 quote is about 1.61 times book by simple math. Analyst moves after the report appear in published coverage. The concern is that premiums and per-share Operating Income declined while the shares rose, and a rising combined ratio cuts into Underwriting margins.

2. Addus HomeCare (NASDAQ:ADUS)

On the 52-week high screen, Addus HomeCare (NASDAQ:ADUS) is at USD 125.75, up 0.17%, on 508,400 shares (relative volume 2.34), with a USD 2.35 billion market cap, a 52-week high of USD 127.06, a P/E of 22.06 and EPS of USD 5.70, captured November 4, 2026. Shares at peaks meet no resistance from earlier holders, yet they offer less room for error if results weaken, which applies to ADUS. The release provided no new guidance. On September 14, 2026, Addus agreed to acquire the personal care unit of AccentCare for about USD 275.0 million, adding roughly USD 280 million of annualized revenue, with closing subject to regulatory approvals. A BofA downgrade appears in published coverage dated October 28 to 29, 2026. The concern is that the AccentCare transaction still needs regulatory sign-off, no guidance came with the release, and an analyst downgrade preceded the report.

3. Arthur J. Gallagher (NYSE:AJG)

Arthur J. Gallagher (NYSE:AJG) is at USD 278.89, USD 2.64 under its 52-week high of USD 281.53, with Revenue up 18%. AJG is on the list because it sits at or near its price record or its one year peak, a momentum signal. The screen displays a P/E of 42.60 and EPS of USD 6.55. Published market data placed the one year low at USD 190.75, so USD 278.89 sits about 46% above it, by simple math. The company acquired The Mund Group on October 21, 2026 and a Melbourne firm on October 19, 2026, while Pen Underwriting acquired Ornella Underwriting of Ireland on October 7, 2026; terms were not disclosed. The worry is a P/E of 42.60 after a 46% climb from the low, undisclosed deal terms, and growth figures from one source.

4. Alerus Financial (NASDAQ:ALRS)

On the 52-week high screen, Alerus Financial (NASDAQ:ALRS) is at USD 34.63, up 4.40%, on 177,090 shares (relative volume 1.46), with a USD 863.24 million market cap, a 52-week high of USD 34.72, a P/E of 29.32 and a 2.59% dividend yield, captured November 4, 2026. A peak gives the price level, not the value, so the report and valuation behind ALRS need checking. Piper Sandler lifted the stock to Overweight with a USD 38 target in early October 2026, and the board authorized a repurchase of up to 1.25 million shares on August 27, 2026. Third quarter Earnings remain unconfirmed, and the reason for the 4.40% advance was not found. The worry is unverified third quarter EPS, an unexplained jump and a price reference older than the screen.

5. Amneal Pharmaceuticals (NASDAQ:AMRX)

Amneal Pharmaceuticals (NASDAQ:AMRX) dropped 4.97% to USD 20.44 after touching a 52-week high of USD 21.68, despite lifting its 2026 guidance. Peaks reveal the price level, not whether the shares are cheap, so the valuation and results behind AMRX deserve scrutiny. On a GAAP basis Amneal lost USD 22 million, or USD 0.06 per share, versus Net Income of USD 2 million a year earlier, citing non-recurring costs tied to the Kashiv Acquisition and a larger tax provision. The company raised 2026 net revenue guidance to USD 3.15 billion to USD 3.25 billion and adjusted EPS guidance to USD 1.04 to USD 1.08. The concern is a GAAP loss and a weaker Cash Flow outlook alongside higher revenue guidance, with the reason for the 4.97% decline unconfirmed.

Where Things Stand

On the filed figures reviewed, ADUS grew adjusted EPS 17.3%, ACGL repurchased USD 1.4 billion of stock, AJG posted revenue up 18% from a single source, ALRS sits USD 0.09 below its high with unverified third quarter EPS, and AMRX dropped 4.97% after lifting guidance, so no single name clearly leads. Highs often come with strong results, yet screens also catch one-time boosts such as special dividends, Tariff refunds and recent listings. Checking what can repeat separates durable strength from a one-off event. Readers comparing these names should keep the screen date and the filing date apart, since the two can fall on different days.